8-K: Summit Therapeutics' Ivonescimab Shows Significant Progression-Free Survival Benefit in Lung Cancer Trial, Overall Survival Trend Not Statistically Significant

Summit Therapeutics announced topline results from its HARMONi Phase III clinical trial for ivonescimab, demonstrating a statistically significant improvement in progression-free survival for EGFR-mutated non-small cell lung cancer patients, though overall survival showed only a positive trend without statistical significance.

Summary

• Summit Therapeutics' Phase III HARMONi clinical trial for ivonescimab in combination with chemotherapy met its primary endpoint of progression-free survival (PFS) in patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who progressed after 3rd generation EGFR TKI therapy.
• Ivonescimab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS with a hazard ratio (HR) of 0.52 (95% CI: 0.41 – 0.66; p<0.00001) compared to placebo plus chemotherapy.
• A positive trend was observed in overall survival (OS) with a hazard ratio of 0.79 (95% CI: 0.62 – 1.01; p=0.057), but it did not achieve statistical significance in the primary analysis.
• The results showed consistency in the magnitude of PFS benefit between Asian and ex-Asia sub-populations, and consistency with the single-region HARMONi-A study.
• No new safety signals were noted; Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported for 56.9% in the ivonescimab arm vs. 50.0% in the chemotherapy alone arm, with fatal TEAEs (excluding disease progression) at 1.8% vs. 2.8% respectively.
• Ivonescimab is a novel PD-1 / VEGF bispecific antibody, engineered by Akeso Inc., with unique cooperative binding characteristics and a tetravalent structure designed to improve efficacy and safety profiles.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The statistically significant and clinically meaningful improvement in progression-free survival is a strong positive, especially given the unmet need in this patient population and the failure of other therapies. However, the lack of statistically significant overall survival, coupled with the FDA's stated requirement for it, introduces a notable negative and potential regulatory hurdle, tempering the overall enthusiasm.

Positives

• Ivonescimab in combination with chemotherapy achieved a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a hazard ratio of 0.52 (p<0.00001).
• The PFS benefit was consistent across both Asian and ex-Asia sub-populations, demonstrating global applicability.
• The safety profile of ivonescimab plus chemotherapy was acceptable and manageable, with no new safety signals identified.
• Ivonescimab's results are consistent with the previously reported single-region HARMONi-A study, reinforcing its potential.
• The therapy addresses a high unmet medical need in 2L+ EGFRm NSCLC, a setting where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials.

Negatives

• Overall survival (OS) showed only a positive trend (HR 0.79) but did not achieve statistical significance (p=0.057) in the primary analysis.
• The FDA has indicated that a statistically significant overall survival benefit is necessary to support marketing authorization, which will weigh into Summit's considerations regarding the timing of a potential Biologics License Application (BLA) filing.

Risks

• Regulatory risk: The lack of statistically significant overall survival (OS) may complicate or delay the Biologics License Application (BLA) filing and potential marketing authorization in the United States, as the FDA noted OS benefit is necessary.
• Clinical trial risk: While positive, the current OS data may not be sufficient for immediate regulatory approval, requiring further follow-up or additional studies.
• Market adoption risk: Despite PFS benefit, the absence of statistically significant OS could impact physician adoption or payer reimbursement compared to therapies with a proven OS benefit.

Future Outlook

Summit Therapeutics intends to file a Biologics License Application (BLA) for ivonescimab plus chemotherapy in the US, though the timing will be influenced by discussions with the FDA, which emphasized the need for a statistically significant overall survival benefit for marketing authorization. A more complete data presentation from the HARMONi study is planned for a future major medical conference. The company is also continuing other Phase III trials for ivonescimab, including HARMONi-3 and HARMONi-7.

Management Comments

• Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics, stated: "The evidence of a consistent benefit in PFS for both Asian and western patients, as well as the consistent overall survival results between the single-region HARMONi-A study and our global HARMONi study demonstrates the potential benefit ivonescimab has to bring to patients around the world, including the United States."
• Dr. Maky Zanganeh, President and Co-CEO of Summit, added: "Our conviction in the promise that this therapy holds for patients continues to be validated: we believe that ivonescimab has the potential to make a meaningful difference for the betterment of patients lives."

Industry Context

The HARMONi trial's success in progression-free survival is notable in the context of EGFR-mutated NSCLC patients who have progressed after 3rd generation EGFR TKI therapy, a setting where PD-1 monoclonal antibodies have previously failed to show PFS or OS benefit in global Phase III trials. Ivonescimab's differentiated mechanism as a PD-1 / VEGF bispecific antibody, with unique cooperative binding and tetravalent structure, positions it as a potential improvement over existing standards of care and immune checkpoint inhibitors, particularly where both PD-1 and VEGF are highly expressed in the tumor microenvironment.

Comparison to Industry Standards

• Ivonescimab's statistically significant PFS benefit (HR 0.52) in 2L+ EGFRm NSCLC after 3rd generation EGFR TKI therapy contrasts with previous Phase III global clinical trials of PD-1 monoclonal antibodies, which have been unsuccessful in demonstrating either a PFS or OS benefit in this specific patient population.
• The consistency of results between the multiregional HARMONi study and the single-region HARMONi-A study (which showed an OS HR of 0.80 at 52% data maturity) suggests a robust and reproducible effect for ivonescimab.
• The positive trend in overall survival (HR 0.79) for ivonescimab, while not statistically significant, is observed in a setting where no current FDA-approved regimens have demonstrated a statistically significant overall survival benefit, highlighting a potential advancement if further data confirms significance.

Stakeholder Impact

• Shareholders: The mixed results (strong PFS but non-significant OS) could lead to volatility in share price, as the path to US market approval is not entirely clear despite clinical benefit.
• Patients: The positive PFS results offer hope for a new treatment option for EGFR-mutated NSCLC patients who have progressed after TKI therapy, addressing a high unmet medical need.
• Physicians/Caregivers: The data provides new information for treatment decisions, though the regulatory uncertainty regarding OS may influence adoption until full approval.

Next Steps

• Summit Therapeutics intends to file a Biologics License Application (BLA) for ivonescimab plus chemotherapy in the United States.
• Summit will determine the timing of the BLA filing based on further review and discussions with the United States Food & Drug Administration (FDA).
• A more complete data presentation from the HARMONi clinical study is intended to be shared at a future major medical conference.
• Continued enrollment and evaluation in ongoing Phase III clinical trials for ivonescimab, including HARMONi-3 and HARMONi-7.

Key Dates

Recommendation

Keywords

Ivonescimab, Non-Small Cell Lung Cancer, NSCLC, EGFR-mutated, Phase III clinical trial, HARMONi, Progression-Free Survival, Overall Survival, Biologics License Application, BLA, PD-1, VEGF, Bispecific antibody, Oncology, Biopharmaceutical